Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 115-122

  Schatz, U ^a   Arneth, B ^a   Siegert, G ^a   Siegels, D ^a   Fischer, S ^a   Julius, U ^a   Bornstein, S R ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Ferric carboxymaltose; Ferric gluconate; Iron deficiency; Iron deficiency anemia; Lipoprotein apheresis; Reticulocytes

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; LIPOPROTEIN;

ABDOMINAL DISCOMFORT; ADULT; ANAPHYLACTIC SHOCK; APHERESIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEADACHE; HUMAN; HYPOTENSION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; MALE; METALLIC TASTE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHAKING; TASTE DISORDER; WEAKNESS;

AGED; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; FERRIC COMPOUNDS; FERRITINS; GERMANY; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS; MALE; MALTOSE; MIDDLE AGED; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME;

EID: 84872862550     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.012     Document Type: Article

References (25)

1. Bramlage C.P., Armstrong V.W., Zapf A., Bramlage P., Mueller G.A., Koziolek M.J. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. Ther Apher Dial 2010, 14(2):136-142.
2. WHO Iron deficiency anaemia: assessment, prevention and control, a guide for programme managers 2001, WHO.
3. Tings T., Schettler V., Cavelo M., Paulus W., Trenkwalder C. Impact of regular LDL apheresis on the development of restless legs syndrome. Move Dis 2004, 19(9):1072-1075.
4. Harrison's principles of internal medicine. 18th ed., p. 844-51.
5. Thomas L., Thomas C., Heimpel H. Neue Parameter zur Diagnostik von Eisenmangelzuständen, Retikulozytenhämoglobin und löslicher Transferrinrezpetor. Deutsches Ärzteblatt 2005, 102(9):A580-A586.
6. Chuang Chiao-Lin, Liu Ren-Shyan, Wie Yau-Huei, Huang Tung-Po, Tarng Der-Cherng Early prediction of response to intravenous iron supplementation by reticulocyte hemoglobin content and high-fluorescence reticulocyte count in hemodialysis patients. Nephrol Dial Transpl 2003, 18:370-377.
7. Choi Jong Weon, Pai Soo Hwan Reticulocyte subpopulations and reticulocyte maturity index (RMI) rise as body iron status falls. Am J Hematol 2001, 67:130-135.
8. Anker S.D., Colet J.C., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New Engl J Med Nov 2009, 361(25):2436-2448. for the FAIR-HF Trial Investigators.
9. Auerbach M., Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Am Soc Hematol 2010, 2010:338-347.
10. ®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009, 23(1):11-16.
11. Bailie G.R. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung 2010, 60(6a):386-398.
12. Jahn M.R., Andreasen H.B., Fütterer S., et al. A comparative study of the physiochemical properties of iron isomaltoside 1000, a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011, 78:480-491.
13. Julius U., Frind A., Tselmin S., Kopprasch S., Poberschin I., Siegert G. Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther 2008, 6:629-639.
14. Schettler V., Wieland E., Armstrong V.W., Kleinoeder T., Grunewald R.W., Muller G.A. First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management. Ther Apher 2002, 6:381-383.
15. Macdougall I.C., Chandler G., Armstrong A., Breen C., Harchowal J., Cavill I. Characterization of iron availability from three different i.v. iron preparations in dialysis patients. J Am Soc Nephrol 1997, 8:22.
16. Wish J.B. Intravenous iron: not just for hemodialysis patients anymore. Peritoneal Dial Int 2008, 28:126-129.
17. Toblli J.E., Cao G., Olivieri L., Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transpl 2010, 10:3631-3640.
18. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patient with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007, 18:975-984.
19. Moore R.A., Gaskell H., Rose P., Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. Blood Disord 2001, 11:4.
20. Michael B., Coyne D.W., Fishbane S., et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002, 61:1830-1839.
21. Michael B., Coyne D.W., Folkert V.W., Dahl N.V., Warnock D.G. Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transpl 2004, 19:1576-1580. Ferrlecit Publication Committee.
22. Aronoff G.R., Bennett W.M., Blumenthal S., et al. Iron sucrose in haemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004, 66:1193-1198.
23. Silverstein S.B., Rodgers G.M. Parenteral iron therapy options. Am J Hematol 2004, 76:74-78.
24. Rozen-Zvi B., Gafter-Gvili A., Paul M., Leibovici L., Shpilberg O., Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis November 2008, 52(5):897-906.
25. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006, 47(5 Suppl. 3):S11-S145.